Type II endometrial carcinomas are estrogen independent, poorly differentiated tumors that behave in an aggressive manner. Since TP53 mutation and CDH1 inactivation occur in 80% of human endometrial type II carcinomas, we hypothesized that mouse uteri lacking both Trp53 and 
INTRODUCTION
Endometrial cancer is the most common malignancy of the female genital tract, affecting over 52,000 women and leading to approximately 8,500 deaths in the US each year. 1 Two types of endometrial carcinomas (ECs) have been distinguished, type I (T1EC) and type II (T2EC). 2 T1ECs, which account for 80% of all ECs, are associated with hyperestrogenism, have a good prognosis, exhibit atypical hyperplasia, and usually develop in pre-and perimenopausal women. 3, 4 T2ECs are high-grade, estrogen-independent, and diagnosed mainly in post-menopausal women. Although only 15-20% of ECs belong to T2ECs, these tumors appear to be very aggressive, and more than 50% of patients present with recurrent disease shortly after primary treatment. [5] [6] [7] Further, less than 30% of the patients with T2ECs survive 5 years after initial diagnosis. 5 Therefore, a clear understanding of the mechanisms involved in tumor development of T2ECs is necessary for early stage diagnosis as well as rational design of therapies.
T2ECs are poorly differentiated, aggressive tumors. [8] [9] [10] The most common histological tumor type is serous carcinoma comprised of atypical cells that grow into papillary, glandular or solid tumors. 8, 9, 11 A number of studies have reported that TP53 mutations are associated with poor prognosis. 4, 8, 12 Inactivation of TP53 renders cells non-responsive to signals that challenge genomic integrity, thereby promoting the acquisition of novel and harmful cellular phenotypes that are characteristic of cancer cells, such as resistance to apoptosis, neoangiogenesis, and enhanced proliferative and invasive potential. Approximately 80% of T2ECs harbor TP53 mutations. Although TP53 mutations are less common in T1ECs, those reported have been largely confined to high grade tumors (grade 3 and 4). 8 In addition to TP53 mutation, inactivation of CDH1 is also a common molecular feature in T2ECs. 4, 10 CDH1 is critical in the establishment of cell polarity and maintenance of the epithelial phenotype. 13 CDH1 is often downregulated or lost during tumor progression, [14] [15] [16] [17] leading to increased tumor invasiveness and metastasis. 4, [18] [19] [20] [21] [22] Mice with either Trp53 heterozygous or homozygous deletion develop a variety of cancers with most homozygous mice dying by 6-mo due to development of widespread lymphoma, but Trp53-null mice rarely form ECs. [23] [24] [25] Pgr Cre/+ mice have been recognized as an excellent model to target genes in the uterus after birth. 26 While conditional uterine ablation of Pten driven by Pgr-Cre results in development of T1ECs in mice, 27, 28 the uteri of mice lacking Trp53 alone do not exhibit any abnormal morphology by 5-mo. 27 We have recently reported that conditional ablation of Cdh1 in the mouse uterus results in a disorganized cellular structure of the epithelium and ablation of endometrial glands, leading to implantation defects. 29 However, loss of Cdh1 alone in the uterus does not predispose mice to tumors. Conditional ablation of Cdh1 does not induce tumors in mammary glands [30] [31] [32] or stomach, 33 whereas loss of Cdh1 and Trp53 induces invasive lobular carcinoma in mammary glands with massive angiogenesis. 31, 32 Thus, these results indicate that single gene ablation in the uterus is not sufficient to understand the etiology of heterogeneous aggressive types of ECs.
In the present study, we generated a mouse model in which Cdh1 and Trp53 were conditionally ablated in the uterus. Ablation of Trp53 and Cdh1 accelerated endometrial neoplastic transformation and induced cell invasion and dissemination. Further, the results of the present study suggest that ablation of Cdh1 and Trp53 in the mouse uterus initiates chronic inflammation with tumor microenvironment modification which promotes aggressive ECs.
RESULTS

Generation of mice with Cdh1 and Trp53 ablation in the mouse uterus
Because TP53 mutation and CDH1 inactivation are the two most common found molecular features in human T2ECs, 3, 4 our objective was to study the combined effect of dysfunctional uterine TRP53 and CDH1. As Cdh1-null mice show early embryonic lethality, 34, 35 we conditionally deleted both Cdh1 and Trp53 in the uterus using Pgr Cre/+ mice. Pgr Cre/+ mice were crossed with Cdh1 f/f and/or Trp53 f/f mice to provide a tissuespecific knockout of Cdh1 and/or Trp53 in Pgr-expressing cells: Figure 1) . The ability of Pgr-Cre to mediate ablation of Cdh1 and Trp53 in the uterus was confirmed by CDH1 immunoreactivity and Trp53 mRNA analysis (Supplementary Figure 1bc) . Although Cre recombinase in Pgr Cre/+ mice is active in all cell types of the uterus, ablation of both Cdh1 and Trp53 in the uterus only occurs in the epithelial cells as endogenous CDH1 is expressed only in the uterine epithelium. While PGR is expressed in the oviduct, ovary, mammary gland and pituitary, we did not see any histological and/or functional abnormalities in other tissues lacking Cdh1 and Trp53 (data not shown).
Impact of conditional ablation of Cdh1 and Trp53 in the uterus
were generated. While ovarian function in all genotypes was normal, we performed ovariectomy at 6 weeks of age in order to mimic the human disease as T2ECs are estrogen independent and diagnosed mainly in postmenopausal women. Because our first screen in six different genotypes revealed that heterozygous alleles (Cdh1 (Figure 2k ), which is an example of de-differentiation strongly associated with aggressive tumors. Because poor prognosis in T2ECs relates to a propensity for metastasis, 36 we looked at multiple sites in the mice. We observed the first signs of disseminated tumors throughout the peritoneal cavity in Figure  2o ). These results suggest that tumorigenesis in this model proceeds through the recognized morphologic intermediates leading to metastasis associated with T2ECs. 8, 37 Next, to determine whether an alteration in cell proliferation is occurring in
uteri, we performed immunohistochemical staining for Ki67. Nuclear staining of Ki67 in 12-mo uterine sections was analyzed by ImmunoRatio. 38 In agreement with the lack of changes in uterine gross morphology and histology, only a few cells were Ki67 positive in the uteri from control, 
Chronic inflammation was initiated by ablation of Trp53 and Cdh1
Recent discoveries from both clinical and experimental studies indicate that metastatic progression is an independent process from primary tumor development and acquisition of metastatic competence can occur at an early stage of tumor progression. [39] [40] [41] [42] To identify the genetic markers for early tumor development, we performed microarray analysis using the uteri of 2-mo mice following ablation of Cdh1 and/or Trp53. We have deposited this data in the GEO database (GSE48131). Because single ablation of either Cdh1 or Trp53 did not cause any tumor formation ( Figures 1 and 2 ), four relevant comparisons were used to identify uterine target genes that are significantly regulated by Cdh1 and/or Trp53. We identified 120 genes that were in common between comparison 3 and 4 (fold-change greater than 2 and FDR p < 0.05, Supplementary Figure 4ab ). Differentially expressed genes were classified by functional annotation using DAVID analysis 43, 44 and IPA program (Ingenuity Systems, Mountain View, CA). These 120 genes were categorized into groups of inflammatory response (43) , immune cell trafficking (38) , cell-to-cell signaling and interaction (43) , cellular movement (40), cellular growth and proliferation (44) , and tissue morphology (39) (Supplementary Figure 4c) . The results also revealed that most of the genes overlapped in multiple categories of indicated functional annotations, suggesting that Cdh1 d/d Trp53 d/d uteri cause inflammation related to aggressive and invasive cell functions. Gene groups were subjected to Gene Set Enrichment Analysis (GSEA) for association of misregulated genes and genetic signatures of various pathways and cellular processes described in the GO, KEGG, Biocarta, and Reactome databases 45 . At an FDR < 20%, 106 gene sets were significantly upregulated following loss of both Cdh1 and Trp53 (Supplementary Table 1 Differentially expressed transcripts were confirmed by quantitative RT-PCR (qPCR) and a summary of representative genes (fold change ± SE compared to control) are provided in Figure 4 . These results clearly highlighted that many genes, especially those related to inflammation, were upregulated in (Figure 4a) . Further, identified genes were still at significantly high levels in (Figure 4a) . Therefore, we speculate that the tumor microenvironment under chronic inflammation represents a central regulator of tumor development leading to cell invasion, dissemination and metastasis. Interestingly, only 4 of 120 genes exhibited decreased expression in
Additionally, clinically relevant genes differentially expressed between human T1ECs and T2ECs have been identified, [46] [47] [48] and gene expression profiles of serous papillary ECs compared to normal endometrium has also been reported. 49 Our model is more similar to that described by Santin et al, thus we also compared our differentially expressed genes to their published data. Cdkn2a, Claudin, Interleukin and MMP genes are significantly increased in both women afflicted with this type of ECs and our transgenic mouse model (Figure 4ab and 49 ).
Inflammatory signaling within the tumor microenvironment
NFκB and STAT3 are emerging as two key players involved in tumor promotion, progression and metastasis related to inflammation. [50] [51] [52] [53] IKKβ-dependent NFκB activation plays a central role in the activation of numerous pro-inflammatory cytokines in multiple cell types including macrophages. 52, 54 Activated NFκB promotes cell proliferation, migration and metastasis by inducing chemokines. 52, 54 Persistent STAT3 activation in malignant cells stimulates cell proliferation, survival, angiogenesis, invasion and tumorpromoting inflammation. 50, 55 STAT3 activation within immune cells enables suppression of anti-tumor immunity and promotes differentiation and recruitment of myeloid cells, specifically tumor associated macrophages (TAM). 50, 55, 56 TAMs are polarized M2 macrophages and are associated with tumor progression, as opposed to the classical macrophages of the M1 phenotype that perform key immune-surveillance and antigenpresentation functions. 57, 58 Therefore, we examined phospho-IKK and phospho-STAT3, as well as known NFκB downstream molecules (COX2 and iNOS), markers for macrophages (CD68) and TAMs (CD163), a known mediator of metastasis (MMP9), as well as phospho-AKT, which is a well-known key player in T1ECs (Figure 5ab) . 10, 37 Immunoreactivity of p-IKK, COX2, iNOS, MMP9 and p-AKT was semiquantitatively scored by H-scored analysis. 59 Nuclear staining of p-STAT3 was analyzed by ImmunoRatio. 38 
EC cells promote the ability of macrophages to stimulate inflammation
Because TAM expression correlates with inflammatory activity in Cdh1 d/d Trp53 d/d uteri, we investigated inflammatory response between EC cells and macrophages. The activity of NFκB is regulated by interaction with inhibitory IκB proteins. Therefore, we first determined IκB in KLE and AN3CA T2EC cells, RAW264.7 mouse macrophage cells, and RK3E rat epithelial cells as a control. IκB was absent or low abundant in AN3CA or KLE cells, whereas IκB was positive in RK3E and RAW264.7 cells (Figure 6a ). KLE and AN3CA cells were chosen for this study due to the mutation status of TP53 in both cell lines and absence of CDH1 in AN3CA cells (Figure 6a ). When these cells were treated with an NFκB signaling inhibitor, dexamethasone (0, 0.1, 1 or 10 μM) for 24 h, IκB was dosedependently increased in AN3CA cells, but not in KLE and RK3E cells (Figure 6b ), suggesting that AN3CA cells have intact NFκB signaling, but other cells do not. S100A8 and IL1B were the only two factors from our microarray that were detectable in AN3CA cells, and their expression levels were decreased by dexamethasone (Figure 6c) . In our mouse model, CD68 and CD163 were positive in Cdh1 d/d Trp53 d/d uteri ( Figure 5 ). Thus, we hypothesize that interaction of cancer cells and macrophages initiate tumor microenvironment via inflammation and promote tumor growth and progression in ECs. Therefore, we next investigated whether AN3CA-derived factors were able to activate NFκB signaling and stimulate inflammatory related genes in macrophages. We observed that IκB protein was reduced in RAW264.7 cells primed in media conditioned by AN3CA cells (Figure 6d) . A dose-dependent increase in IκB was seen in RAW264.7 cells cultured with conditioned media from AN3CA cells that were treated with a dose range of dexamethasone (Figure 6e ). Further, genes identified by microarray, Il1b, Ppbp, S100a8, Cxcr2 and Cxcl5 were stimulated in RAW264.7 cells primed with conditioned media from AN3CA cells compared to RAW264.7 cells primed with RK3E conditioned media. Increased levels of these genes in RAW264.7 cells primed with AN3CA conditioned media were suppressed when AN3CA cells were treated with dexamethasone prior to collecting conditioned media (Figure 6f ). However, we did not see any differences in Ccl9, Csf3r, Il1rn and Clec7a in RAW264.7 cells cultured with conditioned media from vehicle or dexamethasone treated AN3CA cells. S100a9 and Ccl17 were undetectable in RAW264.7 cells. We used Il6 as a positive control for activated NFκB signaling in RAW264.7 cells. 62 These findings indicate that NFκB signaling in EC cells results in production of inflammation-related factors that stimulate macrophages and contribute to the development of the tumor microenvironment.
DISCUSSION
TP53 mutation occurs in 80% of T2ECs. 3, 4 Recent genome-wide analysis has also confirmed high rates (81.6%) of somatic mutation in TP53 in serous ECs. 63 Loss of CDH1 function through genetic or epigenetic mechanisms has been implicated in the progression and metastasis of numerous malignancies. 21, [64] [65] [66] [67] [68] [69] [70] Negative or reduced expression of CDH1 is one of the features of T2ECs associated with aggressive and invasive characteristics. 10, 15, 71, 72 In our model, however, mice with single gene ablation of Trp53 or Cdh1 in the uterus did not develop ECs, indicating that inactivation of Trp53 or Cdh1 alone does not contribute to tumor initiation and progression. On the other hand, loss of Trp53 along with Cdh1 ablation induces ECs similar to human T2ECs. We report that ablation of Trp53 and Cdh1 accelerates the features of neoplastic transformation in the uterus by inducing myometrial invasion, proliferation, angiogenesis, tumor dissemination, abnormal steroid hormone receptor expression and chronic inflammation.
Histological features of Cdh1 d/d Trp53 d/d uteri exhibited papillary proliferation of small sized cells of the surface epithelium that have very hyperchromatic nuclei similar to T2ECs
pathogenesis, while ablation of Trp53 and Cdh1 did not induce well differentiated epithelial hyperplasia, which is one of the features of T1ECs. One of the key features between T1ECs and T2ECs is steroid hormone dependency. It is known that T2ECs are estrogenindependent, while T1ECs are an estrogen-dependent disease. 3, 4 Expression of ESR1 and PGR in ECs usually signifies that the tumors are well differentiated. Progestin hormone therapy has been used to slow the growth of T1ECs due to its inhibitory effects on estrogen action. However, hormone therapy does not work in T2ECs, because expression of these receptors declines in tumors that are poorly differentiated or of higher grade. 73 75 Inflammation has been established as a frequent tumor promoter through alteration of the tumor microenvironment. 76 The tumor microenvironment is expected to consist of inflammatory cells (TAM and neutrophils etc) in addition to the cancer cells and their surrounding cells (cancer associated-fibroblasts, endothelial and mesenchymal cells). 52, 53, 77, 78 These diverse cells will communicate with each other by means of direct contact or cytokine and chemokine production, and act in autocrine and paracrine manners to enhance tumor progression. In the present study, we observed detectable CD68 and CD163, as well as increased levels of Arg1 in Cdh1 d/d Trp53 d/d but not in control uteri at 6-or 12-mo. CD68 and CD168 are markers of macrophages and CD163 is specific to TAMs in human cancers including ECs. 79 Arg1 is a useful M2 marker in mice. 60, 61 Thus, our results suggest that not only classically activated macrophages, but also polarized M2 macrophages/TAMs, are involved in our model at this stage. When macrophage cells were cultured with conditioned media from EC cells, abundant chemokines, cytokines and enzymes from our microarray were expressed in the macrophage cells. The expression of these factors correlated with activation of NFκB signaling in cancer cells. Interestingly, these results were clearly recapitulated in macrophage cells that were primed in media conditioned by AN3CA cells, which lack CDH1 and harbor a mutation in TP53, but not by KLE cells, which have abundant CDH1 and mutated TP53. This implies EC cells educate recruited macrophages to become TAMs by inducing the polarization of macrophages toward to the M2 phenotype through production of factors downstream of NFκB signaling in the cancer cells themselves, and stimulate the production of chemokines, cytokines and enzymes related to chronic inflammation by TAMs that contributes to the development of the tumor microenvironment. Although the factors derived from EC cells remain to be investigated, S100A8 and IL1B are potential candidates since both cytokines are produced by cancer cells, especially epithelial cancer cells. [80] [81] [82] We also observed complex angiogenesis and invasion in
Angiogenesis, a critical process in tumor progression, is associated with chronic inflammation. 83, 84 TAMs are also involved in angiogenesis in cancer. 85 While aberrant cellular invasiveness, typically accelerated by loss of CDH1, is a hallmark property of epithelial-to-mesenchymal transition (EMT), the expression of transcriptional repressors of CDH1 was not altered compared to control tissues (data not shown). Thus, any EMT-like characteristics in our model stem from direct deletion of Cdh1 and not alteration of other signaling networks that operate upstream or in conjunction with CDH1 signaling. Further, cellular invasiveness was observed in the uteri of
mice. Therefore, chronic inflammation caused by loss of Trp53 and Cdh1 in the uterus is the suspected cause of invasive and/or EMT-like phenotypes. In support of this, the tumor inflammatory microenvironment can facilitate the breakage of the basement membrane, a process required for the invasion and migration of tumor cells. 77 Collectively, results of the present study indicate that chronic inflammation initiated in our mouse model with Cdh1 and Trp53 ablation modifies the tumor microenvironment and promotes aggressive tumor development. Because elucidation of the molecular pathogenesis underlying T2ECs remains key to the development of novel therapeutic approaches, our mouse model provides valuable information on genetic, temporal and dynamic aspects of the tumor microenvironment in this cancer. However, activation of NFκB signaling is not directly induced by these gene mutations in other cancers, and they exert critical oncogenic functions most likely in cancer and immune cells within the microenvironment. 85 Therefore, the precise mechanism of NFκB signaling activated by absence of TP53 and CDH1 remains to be investigated.
MATERIALS AND METHODS
Animals and tissue collection
Mice were maintained in the vivarium at Southern Illinois University according to the institutional guidelines for the care and use of laboratory animals. B6.129-Pgr tm2(cre)Lyd (aka Pgr cre/+ ) mice were provided by Drs. Franco DeMayo and John Lydon. 86 B6.129-Cdh1 tmKem2 /J (aka Cdh1 flox , Jax #005319) and FVB.129-Trp53 tm1Brn (aka Trp53 flox , #01XC2) were obtained from the Jackson Laboratory and the Mouse Models of Human Cancers Consortium, NIH, respectively. The uteri were collected at various time points, and uterine tissues were fixed in fresh 4% paraformaldehyde in PBS at room temperature for 8-12 h and embedded in paraffin, or snap-frozen in liquid nitrogen and stored at −80 °C.
Immunohistochemical analysis
Immunolocalization of Ki67, CD31, ESR1, PGR, p-IKK, p-STAT3, CD68, CD163, COX2, iNOS, MMP9 and p-AKT was determined in cross-sections (5 μm) of paraffin-embedded uterine sections using specific primary antibodies and a Vectastain Elite ABC Kit (Vector laboratories, Burlingame, CA, USA) or DyLight-conjugated secondary antibody (Jackson ImmunoResearch Lab, West Grove, PA, USA). Antibodies used in these analyses were: anti-CDH1 (1:120 
Microarray and qPCR analyses
Total RNA was isolated from mouse uterus using the RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA quality was assessed, and then RNA probes were generated and hybridized to mouse WG-6 v2 Beadchip kit (Illumina, San Diego, CA, USA) in the Functional Genomics Core Facility of University of Illinois. Array data were processed in R (2.14.1) using the limma (3.10.2) BioConductor package.
QPCR was performed following MIQE guidelines described in Supplementary Table 2 . Primers are shown in Supplementary Table 3 for mice and Supplementary Table 4 for human.
Cell culture
AN3CA, KLE, RAW 264.7 and RK3E were purchased from American Type Culture Collection (ATCC). All cells were authenticated by short tandem repeat (STR) analysis and passaged within 6-mo of receipt. Further, all cells were tested routinely for cell proliferation and BrdU incorporation as well as mycoplasma contamination, and they showed similar growth rate and negative mycoplasma during the experiment. All cells were cultured in DMEM with 10% FBS, 200 mM glutamine and penicillin/streptomycin and grown at 37 °C in a humidified 5% CO2 incubator.
Western blot analysis
Ten micrograms of total protein from the cell lysates were separated on SDS-PAGE gels and transferred to nitrocellulose membranes (Millipore Corp., Bedford, MA, USA). Membranes were blocked and incubated overnight with primary antibodies: anti-IκB (1:500 dilution, 9242, Cell Signaling Technology), anti-CDH1 (1:1000 dilution, 610181, BD Biosciences), and anti-β-actin (1:500 dilution, ab8229, Abcam). Immunoreactivity was visualized with IRDye 700 or 800 conjugated affinity-purified secondary antibodies (1:10000 dilution, Rockland Immunochemicals, Gilbertsville, PA, USA) using the Odyssey infrared imaging system (Li-COR, Lincoln, NE, USA).
Statistical analysis
Overall survival rates were determined by Kaplan-Meier analysis and P-value was determined by log-rank test using Prism4.0 (GraphPad, San Diego, CA, USA). All experimental data were subjected to one-way ANOVA and differences between individual means were tested by a Tukey multiple-range test using Prism4.0. Tests of significance were performed using the appropriate error terms according to the expectation of the mean squares for error. A P-value of 0.05 or less was considered significant. Data are presented as least-square means with standard error of the mean.
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Refer to Web version on PubMed Central for supplementary material. analysis. (f) Relative mRNA levels shown in Figure 4a were analyzed in RAW 264.7 cells primed in media conditioned by RK3E or vehicle/dexamethasone treated-AN3CA cells.
